30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Fulcrum Therapeutics Inc (FULC)

Track

Stock chart
Ticker: FULC Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Gould Robert J
1 sale — total 160,857 USD
Planned sale 2 Feb 2026
Value US$3,883,978.79 | Price 201.32 | Shares 53,646
Planned sale 2 Jan 2026
Value US$4,869,728.37 | Price 62.25 | Shares 12,273
Planned sale 15 Dec 2025
Value US$44,599.84 | Price 12.92 | Shares 3,452
Proposed sale 15 Dec 2025
Value US$44,876.00 | Price 13.00 | Shares 3,452
Sale 8 Dec 2025
Value US$1,373,995.56 | Price 14.98 | Shares 91,722
Sale 8 Dec 2025
Value US$38,647,349.16 | Price 14.28 | Shares 2,706,397
Sale 8 Dec 2025
Value US$18,355,676.60 | Price 13.33 | Shares 1,377,020
Proposed sale 8 Dec 2025
Value US$54,235,055.61 | Price 12.99 | Shares 4,175,139
Planned sale 19 Nov 2025
Value US$165,495.00 | Price 11.03 | Shares 15,000
Proposed sale 19 Nov 2025
Value US$437,850.00 | Price 9.73 | Shares 45,000
Planned sale 8 May 2025
Value US$2,519.88 | Price 5.06 | Shares 498
Sale 7 May 2024
Value US$1,831.36 | Price 7.76 | Shares 236
Proposed sale 8 Mar 2024
Value US$57,218.20 | Price 11.72 | Shares 4,884
Planned sale 8 Mar 2024
Value US$57,218.50 | Price 11.72 | Shares 4,884
Buy 4 Mar 2024
Value US$492,027.60 | Price 11.35 | Shares 43,360
Sale 10 May 2023
Value US$695.10 | Price 3.31 | Shares 210
Buy 20 Jan 2023
Value US$24,999,988.00 | Price 13.00 | Shares 1,923,076
Planned sale 13 Jan 2023
Value US$101,490.00 | Price 15.00 | Shares 6,766
Buy 4 Jan 2023
Value US$455,091.42 | Price 7.80 | Shares 58,369
Buy 4 Jan 2023
Value US$859,714.42 | Price 7.03 | Shares 122,334
Buy 27 Dec 2022
Value US$24,509.87 | Price 5.99 | Shares 4,089
Buy 19 Dec 2022
Value US$582,813.66 | Price 5.90 | Shares 98,787
Buy 16 Dec 2022
Value US$7,269,825.69 | Price 5.42 | Shares 1,341,420
Buy 15 Dec 2022
Value US$1,302,474.36 | Price 5.50 | Shares 237,029
Buy 14 Dec 2022
Value US$4,501,573.86 | Price 5.46 | Shares 824,600
Planned sale 7 Jun 2022
Value US$577,894.86 | Price 8.09 | Shares 71,435
Planned sale 6 Jun 2022
Value US$197,591.73 | Price 8.10 | Shares 24,382
Planned sale 3 Jun 2022
Value US$203,056.35 | Price 7.95 | Shares 25,551
Planned sale 2 Jun 2022
Value US$132,161.86 | Price 7.92 | Shares 16,689
Planned sale 7 Apr 2022
Value US$135,228.46 | Price 24.02 | Shares 5,631
Planned sale 5 Apr 2022
Value US$1,274,774.88 | Price 24.26 | Shares 52,552
Planned sale 4 Apr 2022
Value US$173,749.25 | Price 24.02 | Shares 7,235
Planned sale 1 Apr 2022
Value US$828,159.58 | Price 24.03 | Shares 34,464
Planned sale 11 Aug 2021
Value US$665,000.00 | Price 23.75 | Shares 28,000
Planned sale 10 Aug 2021
Value US$560,000.00 | Price 17.50 | Shares 32,000
Buy 28 Jun 2021
Value US$9,802.88 | Price 9.01 | Shares 1,088
Buy 28 Jun 2021
Value US$20,700.00 | Price 9.00 | Shares 2,300
Buy 28 Jun 2021
Value US$10,076.00 | Price 9.16 | Shares 1,100
Buy 28 Jun 2021
Value US$91,600.00 | Price 9.16 | Shares 10,000
Planned sale 16 Mar 2021
Value US$9,805.61 | Price 12.43 | Shares 789
Planned sale 15 Mar 2021
Value US$111,772.72 | Price 12.13 | Shares 9,211
Planned sale 22 Feb 2021
Value US$73,581.50 | Price 14.72 | Shares 5,000
Planned sale 16 Feb 2021
Value US$24,367.08 | Price 14.56 | Shares 1,673
Planned sale 16 Feb 2021
Value US$92,830.33 | Price 14.19 | Shares 6,542
Planned sale 21 Jan 2021
Value US$92,498.00 | Price 14.00 | Shares 6,607
Planned sale 20 Jan 2021
Value US$120,826.00 | Price 12.08 | Shares 10,000
Planned sale 8 Jul 2020
Value US$59,020.00 | Price 20.00 | Shares 2,951
Planned sale 8 Jul 2020
Value US$50,000.00 | Price 20.00 | Shares 2,500
Planned sale 1 Jul 2020
Value US$19,599.30 | Price 18.30 | Shares 1,071
Planned sale 30 Jun 2020
Value US$2,820.00 | Price 20.00 | Shares 141
Planned sale 25 Jun 2020
Value US$32,098.00 | Price 22.00 | Shares 1,459
Planned sale 25 Jun 2020
Value US$51,992.00 | Price 20.80 | Shares 2,500
Planned sale 10 Jun 2020
Value US$8,822.00 | Price 22.00 | Shares 401
Planned sale 9 Jun 2020
Value US$3,120.00 | Price 20.00 | Shares 156
Planned sale 5 Jun 2020
Value US$69,251.16 | Price 20.17 | Shares 3,433
Planned sale 5 Jun 2020
Value US$9,100.77 | Price 20.18 | Shares 451
Planned sale 4 Jun 2020
Value US$4,531.25 | Price 20.05 | Shares 226
Planned sale 4 Jun 2020
Value US$26,057.98 | Price 20.04 | Shares 1,300
Planned sale 3 Jun 2020
Value US$30,192.45 | Price 20.13 | Shares 1,500
Planned sale 3 Jun 2020
Value US$6,819.59 | Price 20.18 | Shares 338
Planned sale 2 Jun 2020
Value US$900.00 | Price 20.00 | Shares 45
Planned sale 2 Jun 2020
Value US$55,940.00 | Price 20.00 | Shares 2,797
Planned sale 1 Jun 2020
Value US$100.00 | Price 20.00 | Shares 5
Planned sale 29 May 2020
Value US$4,007.00 | Price 20.04 | Shares 200
Planned sale 29 May 2020
Value US$27,910.78 | Price 20.08 | Shares 1,390
Planned sale 28 May 2020
Value US$12,000.00 | Price 20.00 | Shares 600
Planned sale 28 May 2020
Value US$44,640.00 | Price 20.00 | Shares 2,232
Planned sale 28 May 2020
Value US$38,391.13 | Price 20.01 | Shares 1,919
Planned sale 27 May 2020
Value US$8,960.00 | Price 20.00 | Shares 448
Planned sale 26 May 2020
Value US$8,240.00 | Price 20.00 | Shares 412
Planned sale 26 May 2020
Value US$50,000.00 | Price 20.00 | Shares 2,500
Planned sale 12 May 2020
Value US$33,480.00 | Price 18.00 | Shares 1,860
Planned sale 11 May 2020
Value US$120,000.00 | Price 16.00 | Shares 7,500
Planned sale 2 Mar 2020
Value US$5,709.53 | Price 18.13 | Shares 315
Planned sale 2 Mar 2020
Value US$31,545.25 | Price 17.26 | Shares 1,828
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-04 2026-02-02 PlS Planned sale
Gould Robert J
Non-Executive Director
53,646 -33.2%
201.32
US$3,883,979 		53,646 -33.2% 201.32 US$3,883,979
2026-01-06 2026-01-02 PlS Planned sale
Gould Robert J
Non-Executive Director
12,273 -28.3%
62.25
US$4,869,728 		12,273 -28.3% 62.25 US$4,869,728
2025-12-17 2025-12-15 PlS Planned sale
2.5
Oltmans Curtis Gale

Chief Legal Officer

Officer
2,984 +3.1%
401.09
US$4,600,048 		2,984 +3.1% 401.09 US$4,600,048
2025-12-15 2025-12-15 PrS Proposed sale
2.5
CURTIS G OLTMANS

Officer

Officer
3,452
13.00
US$44,876 		3,452 13.00 US$44,876
2025-12-10 2025-12-08 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
91,722 -1.5%
14.98
US$1,373,996 		91,722 -1.5% 14.98 US$1,373,996
2025-12-10 2025-12-08 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
2,706,397 -30.6%
14.28
US$38,647,349 		2,706,397 -30.6% 14.28 US$38,647,349
2025-12-10 2025-12-08 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
1,377,020 -13.5%
13.33
US$18,355,677 		1,377,020 -13.5% 13.33 US$18,355,677
2025-12-08 2025-12-08 PrS Proposed sale
RA Capital Healthcare Fund LP

10% Stockholder

Large shareholder
4,175,139
12.99
US$54,235,056 		4,175,139 12.99 US$54,235,056
2025-11-21 2025-11-19 PlS Planned sale
Gould Robert J
Non-Executive Director
15,000 -3.0%
11.03
US$165,495 		15,000 -3.0% 11.03 US$165,495
2025-11-19 2025-11-19 PrS Proposed sale
ROBERT J GOULD

Director

Non-Executive Director
45,000
9.73
US$437,850 		45,000 9.73 US$437,850
2025-05-09 2025-05-08 PlS Planned sale
1.4
Tourangeau Greg

Principal Accounting Officer

Officer
498 -3.4%
5.06
US$2,520 		498 -3.4% 5.06 US$2,520
2024-05-09 2024-05-07 S Sale
1.4
Tourangeau Greg

Principal Accounting Officer

Officer
236 -2.0%
7.76
US$1,831 		236 -2.0% 7.76 US$1,831
2024-03-08 2024-03-08 PrS Proposed sale
1.4
Greg Tourangeau

Officer

Officer
4,884
11.72
US$57,218 		4,884 11.72 US$57,218
2024-03-08 2024-03-08 PlS Planned sale
1.4
Tourangeau Greg

Vice President, Finance

Officer
4,884 -29.3%
11.72
US$57,219 		4,884 -29.3% 11.72 US$57,219
2024-03-05 2024-03-04 B Purchase
0.5
Sapir Alex

See Remarks

Executive Director
43,360 +inf%
11.35
US$492,028 		43,360 +inf% 11.35 US$492,028
2023-05-11 2023-05-10 S Sale
1.4
Tourangeau Greg

Principal Accounting Officer

Officer
210 -1.3%
3.31
US$695 		210 -1.3% 3.31 US$695
2023-01-24 2023-01-20 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
1,923,076 +19.9%
13.00
US$24,999,988 		1,923,076 +19.9% 13.00 US$24,999,988
2023-01-13 2023-01-13 PlS Planned sale
Gould Robert J

Interim President & CEO

Executive Director
6,766 -1.3%
15.00
US$101,490 		6,766 -1.3% 15.00 US$101,490
2023-01-06 2023-01-04 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
58,369 +0.6%
7.80
US$455,091 		58,369 +0.6% 7.80 US$455,091
2023-01-06 2023-01-04 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
122,334 +1.3%
7.03
US$859,714 		122,334 +1.3% 7.03 US$859,714
2022-12-29 2022-12-27 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
4,089 +0.0%
5.99
US$24,510 		4,089 +0.0% 5.99 US$24,510
2022-12-21 2022-12-19 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
98,787 +1.1%
5.90
US$582,814 		98,787 +1.1% 5.90 US$582,814
2022-12-16 2022-12-16 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
1,341,420 +16.6%
5.42
US$7,269,826 		1,341,420 +16.6% 5.42 US$7,269,826
2022-12-16 2022-12-15 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
237,029 +3.0%
5.50
US$1,302,474 		237,029 +3.0% 5.50 US$1,302,474
2022-12-16 2022-12-14 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
824,600 +11.8%
5.46
US$4,501,574 		824,600 +11.8% 5.46 US$4,501,574
2022-06-08 2022-06-07 PlS Planned sale
Gould Robert J
Non-Executive Director
71,435 -12.4%
8.09
US$577,895 		71,435 -12.4% 8.09 US$577,895
2022-06-06 2022-06-06 PlS Planned sale
Gould Robert J
Non-Executive Director
24,382 -4.6%
8.10
US$197,592 		24,382 -4.6% 8.10 US$197,592
2022-06-06 2022-06-03 PlS Planned sale
Gould Robert J
Non-Executive Director
25,551 -4.8%
7.95
US$203,056 		25,551 -4.8% 7.95 US$203,056
2022-06-06 2022-06-02 PlS Planned sale
Gould Robert J
Non-Executive Director
16,689 -3.2%
7.92
US$132,162 		16,689 -3.2% 7.92 US$132,162
2022-04-11 2022-04-07 PlS Planned sale
Gould Robert J
Non-Executive Director
5,631 -1.1%
24.02
US$135,228 		5,631 -1.1% 24.02 US$135,228
2022-04-05 2022-04-05 PlS Planned sale
Gould Robert J
Non-Executive Director
52,552 -9.4%
24.26
US$1,274,775 		52,552 -9.4% 24.26 US$1,274,775
2022-04-05 2022-04-04 PlS Planned sale
Gould Robert J
Non-Executive Director
7,235 -1.4%
24.02
US$173,749 		7,235 -1.4% 24.02 US$173,749
2022-04-05 2022-04-01 PlS Planned sale
Gould Robert J
Non-Executive Director
34,464 -6.4%
24.03
US$828,160 		34,464 -6.4% 24.03 US$828,160
2021-08-12 2021-08-11 PlS Planned sale
Stuart Bryan

See Remarks

Executive Director
28,000 -100.0%
23.75
US$665,000 		28,000 -100.0% 23.75 US$665,000
2021-08-12 2021-08-10 PlS Planned sale
Stuart Bryan

See Remarks

Executive Director
32,000 -100.0%
17.50
US$560,000 		32,000 -100.0% 17.50 US$560,000
2021-06-29 2021-06-28 B Purchase
2.5
Oltmans Curtis Gale

SVP, General Counsel

Officer
1,088 +inf%
9.01
US$9,803 		1,088 +inf% 9.01 US$9,803
2021-06-29 2021-06-28 B Purchase
2.5
Thomson Peter G.

VP Finance & Accounting

Officer
2,300 +inf%
9.00
US$20,700 		2,300 +inf% 9.00 US$20,700
2021-06-29 2021-06-28 B Purchase
2.5
Morabito Christopher

Chief Medical Officer

Officer
1,100 +inf%
9.16
US$10,076 		1,100 +inf% 9.16 US$10,076
2021-06-29 2021-06-28 B Purchase
2.5
GERAGHTY JAMES A
Non-Executive Director
10,000 +12.4%
9.16
US$91,600 		10,000 +12.4% 9.16 US$91,600
2021-03-17 2021-03-16 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
789 -0.2%
12.43
US$9,806 		789 -0.2% 12.43 US$9,806
2021-03-17 2021-03-15 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
9,211 -1.8%
12.13
US$111,773 		9,211 -1.8% 12.13 US$111,773
2021-02-24 2021-02-22 PlS Planned sale
2.5
Thomson Peter G.

VP Finance & Accounting

Officer
5,000 -24.7%
14.72
US$73,582 		5,000 -24.7% 14.72 US$73,582
2021-02-18 2021-02-16 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,673 -0.3%
14.56
US$24,367 		1,673 -0.3% 14.56 US$24,367
2021-02-18 2021-02-16 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
6,542 -1.2%
14.19
US$92,830 		6,542 -1.2% 14.19 US$92,830
2021-01-25 2021-01-21 PlS Planned sale
2.5
Thomson Peter G.

VP Finance & Accounting

Officer
6,607 -30.3%
14.00
US$92,498 		6,607 -30.3% 14.00 US$92,498
2021-01-22 2021-01-20 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
10,000 -1.9%
12.08
US$120,826 		10,000 -1.9% 12.08 US$120,826
2020-07-09 2020-07-08 PlS Planned sale
Wallace Owen B.

Chief Scientific Officer

Officer
2,951 -2.3%
20.00
US$59,020 		2,951 -2.3% 20.00 US$59,020
2020-07-09 2020-07-08 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
2,500 -0.5%
20.00
US$50,000 		2,500 -0.5% 20.00 US$50,000
2020-07-02 2020-07-01 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
1,071 -1.6%
18.30
US$19,599 		1,071 -1.6% 18.30 US$19,599
2020-07-01 2020-06-30 PlS Planned sale
Wallace Owen B.

Chief Scientific Officer

Officer
141 -0.1%
20.00
US$2,820 		141 -0.1% 20.00 US$2,820
2020-06-26 2020-06-25 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
1,459 -2.1%
22.00
US$32,098 		1,459 -2.1% 22.00 US$32,098
2020-06-26 2020-06-25 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
2,500 -0.5%
20.80
US$51,992 		2,500 -0.5% 20.80 US$51,992
2020-06-12 2020-06-10 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
401 -0.6%
22.00
US$8,822 		401 -0.6% 22.00 US$8,822
2020-06-10 2020-06-09 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
156 -0.0%
20.00
US$3,120 		156 -0.0% 20.00 US$3,120
2020-06-09 2020-06-05 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
3,433 -0.6%
20.17
US$69,251 		3,433 -0.6% 20.17 US$69,251
2020-06-08 2020-06-05 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
451 -0.7%
20.18
US$9,101 		451 -0.7% 20.18 US$9,101
2020-06-08 2020-06-04 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
226 -0.3%
20.05
US$4,531 		226 -0.3% 20.05 US$4,531
2020-06-05 2020-06-04 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,300 -0.2%
20.04
US$26,058 		1,300 -0.2% 20.04 US$26,058
2020-06-05 2020-06-03 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,500 -0.3%
20.13
US$30,192 		1,500 -0.3% 20.13 US$30,192
2020-06-04 2020-06-03 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
338 -0.5%
20.18
US$6,820 		338 -0.5% 20.18 US$6,820
2020-06-04 2020-06-02 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
45 -0.1%
20.00
US$900 		45 -0.1% 20.00 US$900
2020-06-03 2020-06-02 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
2,797 -0.5%
20.00
US$55,940 		2,797 -0.5% 20.00 US$55,940
2020-06-03 2020-06-01 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
5 -0.0%
20.00
US$100 		5 -0.0% 20.00 US$100
2020-06-01 2020-05-29 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
200 -0.3%
20.04
US$4,007 		200 -0.3% 20.04 US$4,007
2020-06-01 2020-05-29 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,390 -0.3%
20.08
US$27,911 		1,390 -0.3% 20.08 US$27,911
2020-06-01 2020-05-28 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
600 -0.9%
20.00
US$12,000 		600 -0.9% 20.00 US$12,000
2020-06-01 2020-05-28 PlS Planned sale
Wallace Owen B.

Chief Scientific Officer

Officer
2,232 -1.7%
20.00
US$44,640 		2,232 -1.7% 20.00 US$44,640
2020-06-01 2020-05-28 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
1,919 -0.3%
20.01
US$38,391 		1,919 -0.3% 20.01 US$38,391
2020-05-29 2020-05-27 PlS Planned sale
Wallace Owen B.

Chief Scientific Officer

Officer
448 -0.4%
20.00
US$8,960 		448 -0.4% 20.00 US$8,960
2020-05-28 2020-05-26 PlS Planned sale
Wallace Owen B.

Chief Scientific Officer

Officer
412 -0.3%
20.00
US$8,240 		412 -0.3% 20.00 US$8,240
2020-05-28 2020-05-26 PlS Planned sale
Gould Robert J

See Remarks

Executive Director
2,500 -0.5%
20.00
US$50,000 		2,500 -0.5% 20.00 US$50,000
2020-05-12 2020-05-12 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
1,860 -2.7%
18.00
US$33,480 		1,860 -2.7% 18.00 US$33,480
2020-05-12 2020-05-11 PlS Planned sale
2.5
Thomson Peter G.

VP Finance & Accounting

Officer
7,500 -26.3%
16.00
US$120,000 		7,500 -26.3% 16.00 US$120,000
2020-03-02 2020-03-02 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
315 -0.5%
18.13
US$5,710 		315 -0.5% 18.13 US$5,710
2020-03-02 2020-03-02 PlS Planned sale
Cadavid Diego

SVP Clinical Development

Officer
1,828 -2.7%
17.26
US$31,545 		1,828 -2.7% 17.26 US$31,545
Explore more

More insider trading research around Fulcrum Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America